Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Horwitz Steven; OConnor Owen A.; Pro Barbara; Illidge Tim; Fanale Michelle; Advani Ranjana; Bartlett Nancy L.; Christensen Jacob Haaber; Morschhauser Franck; Domingo-Domenech Eva; Rossi Giuseppe; Kim Won Seog; Feldman Tatyana; Lennard Anne; Belada David; Illes Arpad; Tobinai Kensei; Tsukasaki Kunihiro; Yeh Su-Peng; Shustov Andrei; Savage Kerry J.; Yuen Sam; Iyer Swaminathan; Zinzani Pier Luigi; Hua Zhaowei; Little Meredith; Rao Shangbang; Woolery Joseph; Manley Thomas; Aboulafia David; Alpdogan Onder; Ando Kiyoshi; Arcaini Luca; Baldini Luca; Bellam Naresh; Bartlett Nancy; Ben Yehuda Dina; Benedetti Fabio; Borchman Peter; Bordessoule Dominique; Brice Pauline; Briones Javier; Caballero Dolores; Carella Angelo Michele; Chang Hung; Cheong June Weon; Cho Seok-Goo; Choi Ilseung; Choquet Sylvain; Colita Andrei; Congui Angela Giovanna; Damore Francesco; Dang Nam; Davison Kelly; De Guibert Sophie; Brown Peter de Nully; Delwail Vincent; Demeter Judit; di Raimondo Francesco; Do Young Rok; Domingo Eva; Douvas Michael; Dreyling Martin; Ernst Thomas; Fay Keith; Ferrero Silvia Fernandez; Flinn Ian Winchester; Forero-Torres Andres; Fox Christopher; Friedberg Jonathan; Fukuhara Noriko; Garcia-Marco Jose; Cruz Jorge Gayoso; Codina Jose Gomez; Gressin Remy; Grigg Andrew; Gurion Ronit; Haioun Corinne; Hajek Roman; Hanel Mathias; Hatake Kiyohiko; Hensen Robert; Horowitz Netanel; Huttmann Andreas; Ishizawa Kenichi; Islas-Ohlmayer Miguel; Jacobsen Eric; Janakiram Murali; Jurczak Wojciech; Kaminski Mark; Kato Koji; Kirgner Ilya; Kuo Ching-Yuan; Lazaroiu Mihaela Cornelia; Le Du Katell; Lee Jong-Seok; Legouill Steven; Larosee Paul; Levi Itai; Link Brian; Maisonneuve Herve; Maruyama Dai; Mayer Jiri; McCarty John; McKay Pam; Minami Yosuke; Mocikova Heidi; Morra Enrica; Munoz Javier; Nagai Hirokazu; OConnor Owen; Opat Stephen; Pettengell Ruth; Pezzutto Antonio; Pfreundschuh Michael; Pluta Andrzej; Porcu Pierluigi; Quach Hang; Rambaldi Alessandro; Renwick William; Reyes Ruben; Izquierdo Antonia Rodriguez; Ruan Jia; Rusconi Chiara; Salles Gilles; Santoro Armando; Sarriera Jose; Savage Kerry; Shibayama Hirohiko; Suh Cheolwon; Sureda Anna; Tanimoto Mitsune; Taniwaki Masafumi; Tilly Herve; Trneny Marek; Trumper Lorenz; Tsukamoto Norifumi; Vitolo Umberto; Walewski Jan; Weidmann Eckhart; Wilhelm Martin; Witzens-Harig Mathias; Yacoub Abdulraheem; Yamamoto Kazuhito; Yoon Sung-Soo; Yun Hwan Jung; Zain Jasmine; Zinzan Pier Luigi

首页> 外文期刊>The Lancet >Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

【24h】

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

机译：Brentuximab Vedotin具有化学疗法，用于CD30阳性外周T细胞淋巴瘤（Echelon-2）：全球，双盲，随机，第3期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.

机译：背景技术基于阶段1研究中观察到的令人鼓舞的活动和可管理的安全性，启动了Echelon-2试验以比较Brentuximab Vedotin，环磷酰胺，多柔比星和泼尼松（A + CHP）与环磷酰胺，多柔比星的疗效和安全性长春脉，和泼尼松（Chec）治疗CD30阳性外周T细胞淋巴瘤。

著录项

来源
《The Lancet》 |2019年第10168期|共12页
作者
Horwitz Steven; OConnor Owen A.; Pro Barbara; Illidge Tim; Fanale Michelle; Advani Ranjana; Bartlett Nancy L.; Christensen Jacob Haaber; Morschhauser Franck; Domingo-Domenech Eva; Rossi Giuseppe; Kim Won Seog; Feldman Tatyana; Lennard Anne; Belada David; Illes Arpad; Tobinai Kensei; Tsukasaki Kunihiro; Yeh Su-Peng; Shustov Andrei; Savage Kerry J.; Yuen Sam; Iyer Swaminathan; Zinzani Pier Luigi; Hua Zhaowei; Little Meredith; Rao Shangbang; Woolery Joseph; Manley Thomas; Aboulafia David; Alpdogan Onder; Ando Kiyoshi; Arcaini Luca; Baldini Luca; Bellam Naresh; Bartlett Nancy; Ben Yehuda Dina; Benedetti Fabio; Borchman Peter; Bordessoule Dominique; Brice Pauline; Briones Javier; Caballero Dolores; Carella Angelo Michele; Chang Hung; Cheong June Weon; Cho Seok-Goo; Choi Ilseung; Choquet Sylvain; Colita Andrei; Congui Angela Giovanna; Damore Francesco; Dang Nam; Davison Kelly; De Guibert Sophie; Brown Peter de Nully; Delwail Vincent; Demeter Judit; di Raimondo Francesco; Do Young Rok; Domingo Eva; Douvas Michael; Dreyling Martin; Ernst Thomas; Fay Keith; Ferrero Silvia Fernandez; Flinn Ian Winchester; Forero-Torres Andres; Fox Christopher; Friedberg Jonathan; Fukuhara Noriko; Garcia-Marco Jose; Cruz Jorge Gayoso; Codina Jose Gomez; Gressin Remy; Grigg Andrew; Gurion Ronit; Haioun Corinne; Hajek Roman; Hanel Mathias; Hatake Kiyohiko; Hensen Robert; Horowitz Netanel; Huttmann Andreas; Ishizawa Kenichi; Islas-Ohlmayer Miguel; Jacobsen Eric; Janakiram Murali; Jurczak Wojciech; Kaminski Mark; Kato Koji; Kirgner Ilya; Kuo Ching-Yuan; Lazaroiu Mihaela Cornelia; Le Du Katell; Lee Jong-Seok; Legouill Steven; Larosee Paul; Levi Itai; Link Brian; Maisonneuve Herve; Maruyama Dai; Mayer Jiri; McCarty John; McKay Pam; Minami Yosuke; Mocikova Heidi; Morra Enrica; Munoz Javier; Nagai Hirokazu; OConnor Owen; Opat Stephen; Pettengell Ruth; Pezzutto Antonio; Pfreundschuh Michael; Pluta Andrzej; Porcu Pierluigi; Quach Hang; Rambaldi Alessandro; Renwick William; Reyes Ruben; Izquierdo Antonia Rodriguez; Ruan Jia; Rusconi Chiara; Salles Gilles; Santoro Armando; Sarriera Jose; Savage Kerry; Shibayama Hirohiko; Suh Cheolwon; Sureda Anna; Tanimoto Mitsune; Taniwaki Masafumi; Tilly Herve; Trneny Marek; Trumper Lorenz; Tsukamoto Norifumi; Vitolo Umberto; Walewski Jan; Weidmann Eckhart; Wilhelm Martin; Witzens-Harig Mathias; Yacoub Abdulraheem; Yamamoto Kazuhito; Yoon Sung-Soo; Yun Hwan Jung; Zain Jasmine; Zinzan Pier Luigi;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr New York NY 10065 USA;

Columbia Univ Med Ctr New York NY USA;

Northwestern Univ Feinberg Sch Med Div Hematol &

Oncol Dept Med Chicago IL 60611 USA;

Univ Manchester NIH Div Canc Sci Fac Biol Med &

Hlth Manchester Lancs England;

Univ Texas Houston MD Anderson Canc Ctr 1515 Holcombe Blvd Houston TX 77030 USA;

Stanford Canc Ctr Blood &

Marrow Transplant Program Stanford CA USA;

Washington Univ Sch Med St Louis MO USA;

Odense Univ Hosp Odense Denmark;

Univ Lille Ctr Hosp Univ Lille Grp Rech Formes Injectables &

Technol Assodees Lille France;

Inst Catala Oncol Barcelona Spain;

Azienda Osped Spedali Civili Brescia Brescia Italy;

Samsung Med Ctr Seoul South Korea;

Hackensack Univ Med Ctr Hackensack NJ USA;

Freeman Rd Hosp Newcastle Upon Tyne Tyne &

Wear England;

Charles Univ Prague Dept Internal Med Haematol 4 Hosp &

Fac Med Hradec Kralove Czech Republic;

Univ Debrecen Fac Med Dept Hematol Debrecen Hungary;

Natl Canc Ctr Tokyo Japan;

Saitama Med Univ Int Med Ctr Saitama Japan;

China Med Univ Hosp Taichung Taiwan;

Univ Washington Med Ctr Seattle WA 98195 USA;

Univ British Columbia Vancouver BC Canada;

Calvary Mater Newcastle Hosp Waratah NSW Australia;

Univ Texas Houston MD Anderson Canc Ctr 1515 Holcombe Blvd Houston TX 77030 USA;

Univ Bologna Inst Hematol Seragnoli Bologna Italy;

Millennium Pharmaceut Inc Cambridge MA USA;

Millennium Pharmaceut Inc Cambridge MA USA;

Seattle Genet Inc Bothell WA USA;

Seattle Genet Inc Bothell WA USA;

Seattle Genet Inc Bothell WA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (vol 393, pg 229, 2019) [J] . Horwitz S., OConnor O. A., Pro B. The Lancet . 2019,第10168期

机译：Brentuximab Vedotin具有化学疗法，用于CD30阳性外周T细胞淋巴瘤（Echelon-2）：全球，双盲，随机，第3阶段试验（Vol 393，PG 229,2019）
2. The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas [J] . Horwitz Steven M., OConnor Owen A., Pro Barbara, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Echelon-2试验：随机，双盲，有效控制的Prent vEdotin和ChP（A加CHP）的3研究结果与CD30 +外周T细胞淋巴瘤患者的前线治疗中的CHP（A加CHP）与剁碎
3. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [J] . Prince H. Miles, Kim Youn H., Horwitz Steven M., The Lancet . 2017,第10094期

机译：Brentuximab Vedotin或医生在CD30-阳性皮肤T细胞淋巴瘤（Alcanza）中的选择：国际，开放标签，随机，第3阶段，多期式试验
4. ELEVATION OF MINIMAL RESIDUAL DISEASE (MRD) IN THE PERIPHERAL BLOOD PRIOR TO THE CLINICAL RELAPSE IN DOGS WITH LYMPHOMA THAT ACHIEVED COMPLETE REMISSION AFTER CHEMOTHERAPY [C] . Masahiko Sato, Junpei Yamazaki, Yuko Goto-Koshino, Annual Conference of the Veterinary Cancer Society . 2009

机译：在淋巴瘤患者临床复发之前在外周血中的最小残留疾病（MRD）升高，从而在化疗后取得完全缓解
5. Molecular Characterization of Canine Peripheral T-Cell Lymphoma [D] . Harris, Lauren . 2020

机译：犬外周T细胞淋巴瘤的分子表征
6. Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study [O] . Michelle A. Fanale, Steven M. Horwitz, Andres Forero-Torres, -1

机译：Brentuximab Vedotin在CD30 +周围性T细胞淋巴瘤患者的一线治疗中：I期研究的结果
7. Faculty Opinions recommendation of Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. [O] . Bruce Cheson 2018

机译：Brentuximab Vedotin与CD30阳性外周T细胞淋巴瘤化疗的教师意见建议（Echelon-2）：全球性，双盲，随机，第3期试验。

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅